What we're reading, February 1, 2016: some medical researchers disagree with sharing raw data used in their research; the medical community is torn on whether or not the annual checkup is worthwhile; and Donald Trump vows to extend healthcare coverage to the lower class.
While medical researchers agree in theory with Vice President Joe Biden’s cancer moonshot proposal, the idea of sharing raw data used in research has created dissension among the community, according to POLITICO. The trouble started when New England Journal of Medicine ran an op-ed pointing out that while data sharing was good, it could not be done by so-called “data parasites,” who would misuse work that took researchers years to assemble.
Physicians remain mixed on whether or not the annual checkup is a worthwhile endeavor. The annual checkup was once an unquestioned practice, but now it is being debated with some medical societies recommending against it for healthy adults. USA Today has highlighted some pros and cons of having routine checkups that may help consumers decide whether or not having one is right for them. Included in the lists is the fact that routine checkups provide an opportunity to fit in proven screening and prevention practices (pro) and that routine checkups waste time and money and can actually harm patients sometimes (cons).
Donald Trump continues to set himself apart from his Republican opponents. Although he remains vague on the details, the GOP frontrunner pledged to extend healthcare coverage to the lower class, reported The Hill. However, he denied that he was calling for a single-payer system, as rival Ted Cruz has said. Trump acknowledged that he might lose the election based on his vow.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More